# An Investigational Immuno-therapy Trial of Pomalidomide and Low-dose Dexamethasone With or Without Elotuzumab to Treat Refractory and Relapsed and Refractory Multiple Myeloma (ELOQUENT-3)

> **NCT02654132** · PHASE2 · COMPLETED · sponsor: **Bristol-Myers Squibb** · enrollment: 117 (actual)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** Elotuzumab
- **DRUG:** Pomalidomide
- **DRUG:** Dexamethasone

## Key facts

- **NCT ID:** NCT02654132
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-03-18
- **Primary completion:** 2018-01-17
- **Final completion:** 2021-10-21
- **Target enrollment:** 117 (ACTUAL)
- **Last updated:** 2022-11-01

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02654132

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02654132, "An Investigational Immuno-therapy Trial of Pomalidomide and Low-dose Dexamethasone With or Without Elotuzumab to Treat Refractory and Relapsed and Refractory Multiple Myeloma (ELOQUENT-3)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02654132. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*